The potentiation activity of β-lactam by phomoidrides and oxasetin against methicillin-resistant Staphylococcus aureus

  • J Antibiot (Tokyo). 2024 Mar;77(3):185-188. doi: 10.1038/s41429-023-00691-2.
Masako Honsho  #  1  2 ,  Aoi Kimishima  #  1  2 ,  Akari Ikeda  #  1  2 ,  Masato Iwatsuki  1  2 ,  Kenichi Nonaka  1  2 ,  Hidehito Matsui  1  2 ,  Hideaki Hanaki  1  2 ,  Yukihiro Asami  3  4 ,  Toshiaki Sunazuka  5  6
Affiliations
  • 1. Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
  • 2. Ōmura Satoshi Memorial Institute, Kitasato University, Tokyo, 108-8641, Japan.
  • 3. Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan. [email protected].
  • 4. Ōmura Satoshi Memorial Institute, Kitasato University, Tokyo, 108-8641, Japan. [email protected].
  • 5. Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan. [email protected].
  • 6. Ōmura Satoshi Memorial Institute, Kitasato University, Tokyo, 108-8641, Japan. [email protected].
  • # Contributed equally.
PMID: 38177698 DOI: 10.1038/s41429-023-00691-2
Abstract

Antimicrobial resistance (AMR) causes a global health threat and enormous damage for humans. Among them, Methicillin-resistant Staphylococcus aureus (MRSA) resistant to first-line therapeutic β-lactam drugs such as meropenem (MEPM) is problematic. Therefore, we focus on combination drug therapy and have been seeking new potentiators of MEPM to combat MRSA. In this paper, we report the isolation of phomoidrides A-D and its new analog, phomoidride H along with a polyketide compound, oxasetin from the culture broth of Neovaginatispora clematidis FKI-8547 strain as potentiators of MEPM against MRSA.

Products